Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | GPR27 | Q9NS67 | 8/20 | 0.61 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | PPIA | P62937 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15840633 | 0.91 | ALDH1A1 (0.71) | ALDH1A1GPR27AVPR2LMNAMAPT | |
| SCHEMBL25132396 | 0.87 | ALDH1A1 (0.74) | ALDH1A1GPR27AVPR2LMNAMAPT | |
| SCHEMBL15840711 | 0.87 | ALDH1A1 (0.74) | ALDH1A1GPR27AVPR2LMNAMAPT | |
| SCHEMBL15840632 | 0.85 | ALDH1A1 (0.74) | ALDH1A1GPR27AVPR2LMNAMAPT | |
| SCHEMBL15840806 | 0.85 | ALDH1A1 (0.67) | ALDH1A1GPR27AVPR2LMNAMAPT | |
| SCHEMBL5454021 | 0.84 | ALDH1A1 (0.77) | ALDH1A1MAPTHTTNPC1RAB9A | |
| SCHEMBL3396831 | 0.83 | ALDH1A1 (0.85) | ALDH1A1LMNAMAPTPPIASMN1; SMN2 | |
| SCHEMBL15840807 | 0.83 | ALDH1A1 (0.74) | ALDH1A1GPR27AVPR2LMNAMAPT | |
| SCHEMBL15840704 | 0.82 | ALDH1A1 (0.63) | ALDH1A1GPR27AVPR2LMNAMAPT | |
| SCHEMBL17066583 | 0.80 | GPR27 (0.79) | GPR27AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | ALDH1A1 4348/4885GPR27 914/4885AVPR2 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.